CSF2 and cancer: Clinical trials on GM-CSF are currently being conducted for several cancer types including melanoma, lymphoma, lung cancer, breast cancer, gastrointestinal cancer, and ongoing phase I-III trials support its utility as a potential vaccine for cancer immunotherapy [76,77,78].